Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
EGLN3P1, or egl-9 family hypoxia-inducible factor 3 pseudogene 1, is a genetic locus classified as a pseudogene, related to but distinct from the protein-coding EGLN3 gene. Pseudogenes are similar to functional genes but are typically non-coding and lack conventional biological activity. EGLN3P1 is not known to encode any active protein, does not serve as a receptor or enzyme, and is not a direct target for drug development. While some pseudogenes have been implicated in RNA-based regulation or as possible disease biomarkers, there is no current evidence tying EGLN3P1 to such roles. Its designation as a pseudogene indicates it is not druggable and does not possess classic molecular or functional attributes of therapeutic targets[4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on egl-9 family hypoxia-inducible factor 3 pseudogene 1 (EGLN3P1).